{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T20:13:40Z","timestamp":1774296820776,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.vaccine.2009.10.045","type":"journal-article","created":{"date-parts":[[2009,10,31]],"date-time":"2009-10-31T08:41:45Z","timestamp":1256978505000},"page":"329-337","source":"Crossref","is-referenced-by-count":62,"title":["Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis"],"prefix":"10.1016","volume":"28","author":[{"given":"Iv\u00e1n D.","family":"V\u00e9lez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Gilchrist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 R.","family":"Ram\u00edrez-Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill A.","family":"Ashman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana P.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Y.","family":"Bogatzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Marie","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen D.","family":"Cowgill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco M.","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2009.10.045_bib1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.pt.2006.09.004","article-title":"Leishmaniasis and poverty","volume":"22","author":"Alvar","year":"2006","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2009.10.045_bib2","series-title":"Hunter's tropical medicine and emerging tropical diseases","first-page":"665","article-title":"Leishmaniasis","author":"Magill","year":"2000"},{"issue":"10","key":"10.1016\/j.vaccine.2009.10.045_bib3","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra064142","article-title":"Control of neglected tropical diseases","volume":"357","author":"Hotez","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2009.10.045_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2009.10.045_bib5","unstructured":"WHO. Leishmaniasis: magnitude of the problem; 2009 [cited 2009]. Available from: http:\/\/www.who.int\/leishmaniasis\/burden\/magnitude\/burden_magnitude\/en\/index.html."},{"issue":"9","key":"10.1016\/j.vaccine.2009.10.045_bib6","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1371\/journal.pntd.0000300","article-title":"The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination","volume":"2","author":"Hotez","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2009.10.045_bib7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.trstmh.2005.04.002","article-title":"Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia","volume":"99","author":"Velez","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2009.10.045_bib8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/092986709787458489","article-title":"Leishmaniasis: current treatment and prospects for new drugs and vaccines","volume":"16","author":"Kedzierski","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.vaccine.2009.10.045_bib9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/ije\/15.4.572","article-title":"Controlled field trial of vaccines against new world cutaneous leishmaniasis","volume":"15","author":"Antunes","year":"1986","journal-title":"Int J Epidemiol"},{"issue":"20","key":"10.1016\/j.vaccine.2009.10.045_bib10","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00018-008-8228-6","article-title":"Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant","volume":"65","author":"Casella","year":"2008","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"10.1016\/j.vaccine.2009.10.045_bib11","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.4049\/jimmunol.157.11.5034","article-title":"Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis","volume":"157","author":"Webb","year":"1996","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2009.10.045_bib12","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1128\/IAI.66.7.3279-3289.1998","article-title":"Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family","volume":"66","author":"Webb","year":"1998","journal-title":"Infect Immun"},{"issue":"27\u201328","key":"10.1016\/j.vaccine.2009.10.045_bib13","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1016\/S0264-410X(02)00302-X","article-title":"Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant","volume":"20","author":"Skeiky","year":"2002","journal-title":"Vaccine"},{"issue":"10 Suppl.","key":"10.1016\/j.vaccine.2009.10.045_bib14","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0966-842X(02)02426-5","article-title":"Taking toll: lipid A mimetics as adjuvants and immunomodulators","volume":"10","author":"Persing","year":"2002","journal-title":"Trends Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.045_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1586\/14760584.2.2.239","article-title":"Development of a leishmaniasis vaccine: the importance of MPL","volume":"2","author":"Reed","year":"2003","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2009.10.045_bib16","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/IAI.70.8.4215-4225.2002","article-title":"Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis","volume":"70","author":"Coler","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.10.045_bib17","unstructured":"ICSSC. Monitoring and reporting adverse events: Appendix VII www resource links; February 6, 2003 [cited April 6, 2009]. Available from: http:\/\/www.icssc.org\/Documents\/Resources\/AEManual2003AppendicesFebruary_06_2003%20final.pdf."},{"issue":"47\u201348","key":"10.1016\/j.vaccine.2009.10.045_bib18","doi-asserted-by":"crossref","first-page":"6944","DOI":"10.1016\/j.vaccine.2006.05.016","article-title":"Surrogate markers of immunity to Leishmania major in leishmanin skin test negative individuals from an endemic area re-visited","volume":"24","author":"Nyl\u00e9n","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2009.10.045_bib19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0035-9203(90)90321-5","article-title":"Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with glucantime","volume":"84","author":"Netto","year":"1990","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2009.10.045_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.imlet.2005.01.009","article-title":"T helper (h)1\/Th2 and Leishmania: paradox rather than paradigm","volume":"99","author":"Alexander","year":"2005","journal-title":"Immunol Lett"},{"issue":"11","key":"10.1016\/j.vaccine.2009.10.045_bib21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri933","article-title":"The immunology of susceptibility and resistance to Leishmania major in mice","volume":"2","author":"Sacks","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2009.10.045_bib22","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1128\/IAI.68.4.1760-1764.2000","article-title":"Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection","volume":"68","author":"Ajdary","year":"2000","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2009.10.045_bib23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2249.1993.tb05931.x","article-title":"Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction","volume":"91","author":"Caceres-Dittmar","year":"1993","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2009.10.045_bib24","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI116341","article-title":"Cytokine patterns in the pathogenesis of human leishmaniasis","volume":"91","author":"Pirmez","year":"1993","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.vaccine.2009.10.045_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.humimm.2009.01.007","article-title":"Th1\/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production","volume":"70","author":"Castellano","year":"2009","journal-title":"Hum Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.045_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2249.2003.02299.x","article-title":"Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG","volume":"134","author":"Mahmoodi","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2009.10.045_bib27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.vaccine.2009.10.045_bib28","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1128\/JVI.00228-07","article-title":"Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells","volume":"81","author":"Kannanganat","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.10.045_bib29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/0035-9203(78)90041-X","article-title":"A field trial of a vaccine against American dermal leishmaniasis","volume":"72","author":"Mayrink","year":"1979","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"8530","key":"10.1016\/j.vaccine.2009.10.045_bib30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(87)90116-4","article-title":"Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis","volume":"1","author":"Convit","year":"1987","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2009.10.045_bib31","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0264-410X(94)90342-5","article-title":"Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: skin-test reactivity, T-cell proliferation and interferon-gamma production","volume":"12","author":"Castes","year":"1994","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2009.10.045_bib32","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/0264-410X(94)90149-X","article-title":"Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes: antibody responses to mycobacterial and leishmanial antigens","volume":"12","author":"Sharples","year":"1994","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2009.10.045_bib33","first-page":"232","article-title":"Desarrollo de Inmunoterapia de la Leishmaniasis Cutanea Americana en el Instituto de Biomedicina","volume":"104","author":"Convit","year":"1996","journal-title":"Gaceta Medica de Caracas"},{"issue":"6","key":"10.1016\/j.vaccine.2009.10.045_bib34","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0035-9203(00)90239-6","article-title":"Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial","volume":"94","author":"Velez","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2009.10.045_bib35","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1086\/515265","article-title":"Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up","volume":"177","author":"Armijos","year":"1998","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2009.10.045_bib36","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1086\/375399","article-title":"Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last?","volume":"187","author":"Armijos","year":"2003","journal-title":"J Infect Dis"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2009.10.045_bib37","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.vaccine.2003.06.002","article-title":"Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis","volume":"22","author":"Armijos","year":"2004","journal-title":"Vaccine"},{"issue":"9115","key":"10.1016\/j.vaccine.2009.10.045_bib38","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(98)09552-X","article-title":"Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran","volume":"351","author":"Sharifi","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2009.10.045_bib39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0264-410X(98)00220-5","article-title":"A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran","volume":"17","author":"Momeni","year":"1999","journal-title":"Vaccine"},{"issue":"9241","key":"10.1016\/j.vaccine.2009.10.045_bib40","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(00)03128-7","article-title":"Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan","volume":"356","author":"Khalil","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2009.10.045_bib41","first-page":"468","article-title":"Safety and immunogenicity of an autoclaved Leishmania major vaccine","volume":"77","author":"Khalil","year":"2000","journal-title":"East Afr Med J"},{"issue":"35","key":"10.1016\/j.vaccine.2009.10.045_bib42","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1016\/j.vaccine.2009.05.084","article-title":"Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis","volume":"27","author":"Noazin","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.10.045_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2009.05.084","article-title":"Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis\u2014a meta-analysis","author":"Noazin","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2009.10.045_bib44","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1017\/S0031182006001831","article-title":"Leishmania vaccines: progress and problems","volume":"133","author":"Kedzierski","year":"2006","journal-title":"Parasitology"},{"issue":"22","key":"10.1016\/j.vaccine.2009.10.045_bib45","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.1073\/pnas.92.22.10267","article-title":"Development of a safe live Leishmania vaccine line by gene replacement","volume":"92","author":"Titus","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.vaccine.2009.10.045_bib46","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/IAI.61.8.3351-3359.1993","article-title":"Recombinant vaccinia viruses expressing GP46\/M-2 protect against Leishmania infection","volume":"61","author":"McMahon-Pratt","year":"1993","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2009.10.045_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1128\/IAI.65.1.171-178.1997","article-title":"Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters","volume":"65","author":"McSorley","year":"1997","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2009.10.045_bib48","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1128\/IAI.66.5.1910-1917.1998","article-title":"Genetic control of immune response to recombinant antigens carried by an attenuated Salmonella typhimurium vaccine strain: Nramp1 influences T-helper subset responses and protection against leishmanial challenge","volume":"66","author":"Soo","year":"1998","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2009.10.045_bib49","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1365-2249.1994.tb06044.x","article-title":"Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients","volume":"96","author":"Kurtzhals","year":"1994","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2009.10.045_bib50","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/infdis\/161.6.1313","article-title":"Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine","volume":"161","author":"White","year":"1990","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2009.10.045_bib51","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/IAI.63.5.2062-2069.1995","article-title":"A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice","volume":"63","author":"Wilson","year":"1995","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2009.10.045_bib52","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1128\/IAI.63.11.4261-4267.1995","article-title":"Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response","volume":"63","author":"Handman","year":"1995","journal-title":"Infect Immun"},{"issue":"5210","key":"10.1016\/j.vaccine.2009.10.045_bib53","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.7725103","article-title":"Expression cloning of a protective Leishmania antigen","volume":"268","author":"Mougneau","year":"1995","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2009.10.045_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1006\/expr.1996.4120","article-title":"Cloning of genes and expression and antigenicity analysis of the Leishmania infantum KMP-11 protein","volume":"85","author":"Berberich","year":"1997","journal-title":"Exp Parasitol"},{"issue":"2","key":"10.1016\/j.vaccine.2009.10.045_bib55","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1590\/S0036-46651997000200002","article-title":"Immune responses induced by a Leishmania (Leishmania) amazonensis recombinant antigen in mice and lymphocytes from vaccinated subjects","volume":"39","author":"Fernandes","year":"1997","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"7","key":"10.1016\/j.vaccine.2009.10.045_bib56","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.186.7.1137","article-title":"Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major","volume":"186","author":"Gurunathan","year":"1997","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.vaccine.2009.10.045_bib57","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pt.2005.03.006","article-title":"Second-generation vaccines against leishmaniasis","volume":"21","author":"Coler","year":"2005","journal-title":"Trends Parasitol"},{"issue":"14","key":"10.1016\/j.vaccine.2009.10.045_bib58","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.vaccine.2008.01.023","article-title":"Vaccines for leishmaniasis in the fore coming 25 years","volume":"26","author":"Palatnik-de-Sousa","year":"2008","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09015758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09015758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T10:46:58Z","timestamp":1685184418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09015758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0264410X09015758"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}